CoChat
Sign Up
Cited by 261Schizophrenia research and treatmentNeuroscience and Neuropharmacology ResearchTreatment of Major Depression

The DOI matches its Crossref record; 14 of the 15 references it cites were found in a registry or an index.

A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia

Kinon, Bruce J., Zhang, Lu, Millen, Brian A., Osuntokun, Olawale O., Williams, Judy E., Kollack-Walker, Sara, Jackson, Kimberley, Kryzhanovskaya, Ludmila, Jarkova, Natalia·2011·Journal of Clinical Psychopharmacology
DOI 10.1097/jcp.0b013e318218dcd5
Open this paper in CoChat — free account

Abstract

The primary objective of this study was to test the hypothesis that 1 or more dose levels of LY2140023 monohydrate, an oral prodrug of the potent metabotropic glutamate (mGlu) 2/3 receptor agonist LY404039, given to patients with schizophrenia for 4 weeks would demonstrate significantly greater efficacy than placebo. The HBBI study was a multicenter, randomized, double-blind, parallel, placebo- and active-controlled trial. Male and female patients aged 18 to 65 years who met the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for schizophrenia were randomized in a 2:2:2:2:2:1 ratio to receive 5-, 20-, 40-, or 80-mg LY2140023 monohydrate twice daily, placebo twice daily, or placebo (am) and 15 mg of olanzapine (pm) daily. Efficacy was defined as the change from baseline on the Positive and Negative Syndrome Scale (PANSS) total score assessed at 4 weeks. The primary analysis did not show that any of the 4 LY2140023 monohydrate doses were more efficacious than placebo as measured by the PANSS total score. Similarly, olanzapine did not significantly separate from placebo. A higher-than-anticipated treatment effect (14.6-point improvement) in the placebo group was observed on PANSS total score. LY2140023 monohydrate was generally well tolerated, although 4 patients reported the serious adverse event of convulsion. LY2140023 monohydrate-treated patients showed little change in dopamine-related adverse events and weight. The results of the HBBI study are considered to be inconclusive because LY2140023 monohydrate and the active control olanzapine did not separate from placebo in the treatment of patients with acutely exacerbated schizophrenia. Additional efficacy, safety, and tolerability testing are needed.

Overview

Integrity signals

Registry

Crossref · 10.1097/jcp.0b013e318218dcd5

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

1 of the 15 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

See all 261

Related

See all

Metadata

Authors
Kinon, B. J., Zhang, L., Millen, B. A., Osuntokun, O. O., Williams, J. E., Kollack-Walker, S., Jackson, K., Kryzhanovskaya, L., & Jarkova, N.
Affiliations
Eli Lilly (United States) (US)
Corresponding author
  • Kinon, Bruce J.
  • Zhang, Lu
  • Millen, Brian A.
  • Osuntokun, Olawale O.
  • Williams, Judy E.
  • Jackson, Kimberley
  • Kryzhanovskaya, Ludmila
ORCID
Venue
Journal of Clinical Psychopharmacology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2011-06
Volume
31
Issue
3
Pages
349-355
ISSN
0271-0749 (ISSN-L)
DOI
10.1097/jcp.0b013e318218dcd5
OpenAlex
W2312770619
Cited by
256
References
15
Citations by year
2026: 5 · 2025: 7 · 2024: 9 · 2023: 4 · 2022: 17 · 2021: 9 · 2020: 10 · 2019: 13 · 2018: 12 · 2017: 13 · 2016: 19 · 2015: 28 · 2014: 29 · 2013: 34 · 2012: 39
FWCI
24.04
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
prodrugs, schizophrenia, acute exacerbation of schizophrenia, olanzapine, dose-ranging, PANSS, convulsions, weight change, drug safety and tolerability
MeSH terms
Olanzapine, Assessment of Medication Adherence, Adolescent, Adult, Aged, Amino Acids, Benzodiazepines, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Inpatients, Male, Middle Aged, Prodrugs, Psychiatric Status Rating Scales, Schizophrenia, Antipsychotic Agents, Drug Monitoring, Receptors, Metabotropic Glutamate, Diagnostic and Statistical Manual of Mental Disorders, Medication Adherence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review